Lytix Biopharma Q3 2024: Positive clinical results and strategic advancements strengthen path to commercialization

Oslo, 19 November 2024. Lytix Biopharma ("Lytix") (Euronext Growth Oslo: LYTIX),
a Norwegian immuno-oncology company dedicated to being part of tomorrow's cancer
treatment, today releases its third quarter 2024 results. Lytix achieved
substantial progress in its clinical pipeline, progressing towards
commercialization.
 
"Our progress this quarter underscores Lytix's potential to deliver
transformative treatments for cancer patients," said Øystein Rekdal, CEO of
Lytix Biopharma. "The positive data from our ongoing studies, especially in
basal cell carcinoma and melanoma, reinforce the value of our technology. We now
have clinical results that supports our vision of making Lytix's innovative
therapies accessible to patients worldwide."

Lytix Biopharma's studies are addressing patients with different types of skin
cancer diseases, basal cell carcinoma and melanoma, and its technology shows
promising features also for other large cancer indications. 

Several upcoming milestones
Lytix' lead drug candidate LTX-315 is currently studied in three ongoing phase
II studies